EcoDrugPlus

5-Hydroxytryptamine Receptor 7

Ensembl ID : ENSCGOG00000001635
Gene Symbol: HTR7
3 Cross references
197 Possible Orthologues:

60s Ribosomal Protein L18a

Ensembl ID : ENSCGOG00000018544
Gene Symbol: LOC115005203
3 Cross references
331 Possible Orthologues:

60s Ribosomal Protein L18a-Like

Ensembl ID : ENSCGOG00000018418
Gene Symbol: LOC115005204
2 Cross references
329 Possible Orthologues:

60s Ribosomal Protein L19

Ensembl ID : ENSCGOG00000005230
Gene Symbol: LOC115024941
3 Cross references
349 Possible Orthologues:

60s Ribosomal Protein L19-Like

Ensembl ID : ENSCGOG00000022241
Gene Symbol: LOC115012784
3 Cross references
349 Possible Orthologues:

60s Ribosomal Protein L22

Ensembl ID : ENSCGOG00000007132
Gene Symbol: LOC115021669
3 Cross references
384 Possible Orthologues:

60s Ribosomal Protein L26

Ensembl ID : ENSCGOG00000014091
Gene Symbol: LOC115015005
3 Cross references
477 Possible Orthologues:

60s Ribosomal Protein L3

Ensembl ID : ENSCGOG00000011974
Gene Symbol: LOC115012779
3 Cross references
338 Possible Orthologues:

60s Ribosomal Protein L35

Ensembl ID : ENSCGOG00000010439
Gene Symbol: LOC115013397
3 Cross references
271 Possible Orthologues:

Abl Proto-Oncogene 1, Non-Receptor Tyrosine Kinase

Ensembl ID : ENSCGOG00000007126
Gene Symbol: ABL1
3 Cross references
202 Possible Orthologues:

Adam Metallopeptidase Domain 17

Ensembl ID : ENSCGOG00000002865
Gene Symbol: ADAM17
3 Cross references
209 Possible Orthologues:

Adam Metallopeptidase With Thrombospondin Type 1 Motif 5

Ensembl ID : ENSCGOG00000024136
Gene Symbol: ADAMTS5
3 Cross references
199 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).